Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Proof of Concept Multicenter, Randomized, Double-Blind Study to Assess the Safety and Efficacy of Phage Therapy in Patients With Hip or Knee Prosthetic Joint Infection Due to Staphylococcus Aureus Treated by DAIR

Next Previous
Trial Profile

A Phase II Proof of Concept Multicenter, Randomized, Double-Blind Study to Assess the Safety and Efficacy of Phage Therapy in Patients With Hip or Knee Prosthetic Joint Infection Due to Staphylococcus Aureus Treated by DAIR

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PP 1493 (Primary) ; PP 1815 (Primary)
  • Indications Bone and joint infections; Staphylococcal infections
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms GLORIA
  • Sponsors PHAXIAM Therapeutics

Most Recent Events

  • 13 Nov 2024 According to a PHAXIAM Therapeutics media release, clearance (CTA) from European and UK (MHRA) regulatory authorities to initiate patient enrollment in Europe.
  • 04 Nov 2024 According to a PHAXIAM Therapeutics media release, after successful completion of GLORIA, expected in Q3 2026, PHAXIAM could be eligible for an early access process and could look for getting Conditional Market Approval (CMA), paving the way for pre-commercialization in Europe as early as the second half of 2027.
  • 04 Nov 2024 According to a PHAXIAM Therapeutics media release, the company is about to finalize the filing of the clinical protocol with the main European health authorities3, including the British MHRA. Subject to these approvals, the GLORIA study will be conducted in 7 European countries (France, Germany, UK, Spain, Italy, Netherlands, Sweden) and the United States, making it the most robust phage therapy study in the world.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top